Head-to-head evidence
Diazepam (Libervant) vs Midazolam (Nayzilam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diazepam (Libervant)
Marketed by Aquestive Therapeutics, Inc.
NCT03428360 · Phase 3 · completed
The study treated 130 participants with diazepam buccal film in a single open-label group, without randomization, blinding, or a control arm. Its primary outcomes were safety event counts rather than a controlled clinical comparison, so the findings cannot establish comparative treatment effectiveness.
Midazolam (Nayzilam)
Marketed by UCB
NCT01390220 · Phase 3 · terminated
This was a randomized, triple-blind, placebo-controlled trial in 201 patients, and the primary outcome, control of a seizure cluster with no recurrence, was reached significantly more often with midazolam than with placebo (72 of 134 patients vs 23 of 67, p=0.011).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Libervant)'s landscape · Midazolam (Nayzilam)'s landscape